1. Andrews P.A. and Howell S.B., 1990, Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 36
2. Burchenal J.H., Irani G., Kern K., Lokys L and Turkevich J., 1980, 1,2-Diaminocyclohexane platinum derivatives of potential clinical value. Rec. Res. Cancer Res. 74: 146
3. Calvert A.H., Harland S.J., Newell D.R., Siddik Z.H., Jones A.C., NcElwain T.J., Raju S., Wiltshaw E., Smith I.E., Baker J.M., Peckham M.J. and Harrap K.R., 1982, Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother. Pharmacol. 9: 140
4. de Graeff A., Slebos R.J.C. and Rodenhuis S., 1988, Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother. Pharmacol. 22: 325
5. Eisenhauer E., Swerton K., Sturgeon J., Fine S., O’Reilly S. and Canetta R., 1990, Carboplatin therapy for recurrent ovarian carcinoma: National Cancer Institute of Canada experience and a review of the literature, in: “Carboplatin: Current Perspectives and Future Directions”, P. Bunn, R. Canetta, R. Ozols and M. Rozencweig, eds., W.B. Saunders Company, Philadelphia, p. 133.